BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maloney SM, Hoover CA, Morejon-Lasso LV, Prosperi JR. Mechanisms of Taxane Resistance. Cancers (Basel). 2020;12. [PMID: 33182737 DOI: 10.3390/cancers12113323] [Cited by in Crossref: 42] [Cited by in F6Publishing: 49] [Article Influence: 21.0] [Reference Citation Analysis]
Number Citing Articles
1 Kong Q, Yang J, Li D, Ding Y, Hu Y, Xue X, Shi M, Jiang B, Zhou Y, Zhang M, Hu J, Guo C, Chen J, Han Y. Tongguanteng injection reverses paclitaxel resistance via upregulation of TAB1 expression in ovarian cancer in vitro and in vivo. Journal of Ethnopharmacology 2023;300:115728. [DOI: 10.1016/j.jep.2022.115728] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Apollonova VS, Sidina EI, Tkachenko EV, Malek AV. MicroRNA-dependent mechanisms of taxane resistance in breast cancer. Opuholi ženskoj reproduktivnoj sistemy 2022;18:52-63. [DOI: 10.17650/1994-4098-2022-18-3-52-63] [Reference Citation Analysis]
3 Seborova K, Koucka K, Spalenkova A, Holy P, Ehrlichova M, Sychra T, Chen L, Bendale H, Ojima I, Sandoval-acuña C, Truksa J, Soucek P, Vaclavikova R. Anticancer regimens containing third generation taxanes SB-T-121605 and SB-T-121606 are highly effective in resistant ovarian carcinoma model. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.971905] [Reference Citation Analysis]
4 Schwartz PB, Nukaya M, Berres M, Rubinstein CD, Wu G, Hogenesch JB, Bradfield CA, Ronnekleiv-kelly SM. The Circadian Clock is Disrupted in Pancreatic Cancer.. [DOI: 10.1101/2022.11.01.514735] [Reference Citation Analysis]
5 Saha Detroja T, Detroja R, Mukherjee S, Samson AO. Identifying Hub Genes Associated with Neoadjuvant Chemotherapy Resistance in Breast Cancer and Potential Drug Repurposing for the Development of Precision Medicine. IJMS 2022;23:12628. [DOI: 10.3390/ijms232012628] [Reference Citation Analysis]
6 Cejuela M, Vethencourt A, Pernas S. Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer. Curr Oncol Rep 2022. [PMID: 36255603 DOI: 10.1007/s11912-022-01339-4] [Reference Citation Analysis]
7 Smith ER, Wang J, Yang D, Xu X. Paclitaxel Resistance Related to Nuclear Envelope Structural SturdinessRunning Title: Lamin A/C Expression and Paclitaxel Resistance. Drug Resistance Updates 2022. [DOI: 10.1016/j.drup.2022.100881] [Reference Citation Analysis]
8 Jia L, Gao X, Fang Y, Zhang H, Wang L, Tang X, Yang J, Wu C. TM2, a novel semi-synthetic taxoid, exerts anti-MDR activity in NSCLC by inhibiting P-gp function and stabilizing microtubule polymerization. Apoptosis. [DOI: 10.1007/s10495-022-01767-4] [Reference Citation Analysis]
9 Suleimenov M, Bekbayev S, Ten M, Suleimenova N, Tlegenova M, Nurmagambetova A, Kauanova S, Vorobjev I. Bcl-xL activity influences outcome of the mitotic arrest. Front Pharmacol 2022;13:933112. [DOI: 10.3389/fphar.2022.933112] [Reference Citation Analysis]
10 Martínez-Sifuentes MA, Bassol-Mayagoitia S, Nava-Hernández MP, Ruiz-Flores P, Ramos-Treviño J, Haro-Santa Cruz J, Hernández-Ibarra JA. Survivin in Breast Cancer: A Review. Genet Test Mol Biomarkers 2022;26:411-21. [PMID: 36166738 DOI: 10.1089/gtmb.2021.0286] [Reference Citation Analysis]
11 Romagnoli R, Oliva P, Prencipe F, Manfredini S, Budassi F, Brancale A, Ferla S, Hamel E, Corallo D, Aveic S, Manfreda L, Mariotto E, Bortolozzi R, Viola G. Design, Synthesis and Biological Investigation of 2-Anilino Triazolopyrimidines as Tubulin Polymerization Inhibitors with Anticancer Activities. Pharmaceuticals (Basel) 2022;15:1031. [PMID: 36015179 DOI: 10.3390/ph15081031] [Reference Citation Analysis]
12 Matadamas‐martínez F, Yépez‐mulia L, Pérez‐koldenkova V, Cortés‐benítez F, Leyte‐lugo M, Palacios‐espinosa JF, Rodríguez‐villar K, Soria‐arteche O, Pérez‐villanueva J. Synthesis and Antitumor Activity of 2,3‐Diphenyl‐2 H ‐indazole Derivatives as Potent Antitubulin Agents. ChemistrySelect 2022;7. [DOI: 10.1002/slct.202202056] [Reference Citation Analysis]
13 Ortiz M, Wabel E, Mitchell K, Horibata S. Mechanisms of chemotherapy resistance in ovarian cancer. Cancer Drug Resist 2022;5:304-16. [PMID: 35800369 DOI: 10.20517/cdr.2021.147] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Chmielewski NN, Limoli CL. Sex Differences in Taxane Toxicities. Cancers 2022;14:3325. [DOI: 10.3390/cancers14143325] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Rahman MK, Al-Zubaidi Y, Bourget K, Chen Y, Tam S, Zhou F, Murray M. Preclinical Evaluation of Ixabepilone in Combination with VEGF Receptor and PARP Inhibitors in Taxane-Sensitive and Taxane-Resistant MDA-MB-231 Breast Cancer Cells. J Pharm Sci 2022:S0022-3549(22)00253-2. [PMID: 35700798 DOI: 10.1016/j.xphs.2022.06.009] [Reference Citation Analysis]
16 Chae HK, Oh YI, Park S, An JH, Seo K, Kang K, Chu SN, Youn HY. Retrospective analysis of efficacy and safety of oral paclitaxel for treatment of various cancers in dogs (2017-2021). Vet Med Sci 2022. [PMID: 35633063 DOI: 10.1002/vms3.829] [Reference Citation Analysis]
17 Lukanović D, Kobal B, Černe K. Ovarian Cancer: Treatment and Resistance to Pharmacotherapy. Reprod Med 2022;3:127-40. [DOI: 10.3390/reprodmed3020011] [Reference Citation Analysis]
18 Lei L, Wang X, Tang S. Novel taxanes in development: hopes or hypes? Critical Reviews in Oncology/Hematology 2022. [DOI: 10.1016/j.critrevonc.2022.103727] [Reference Citation Analysis]
19 Currie J, Demeule M, Charfi C, Zgheib A, Larocque A, Danalache BA, Ouanouki A, Béliveau R, Marsolais C, Annabi B. The Peptide-Drug Conjugate TH1902: A New Sortilin Receptor-Mediated Cancer Therapeutic against Ovarian and Endometrial Cancers. Cancers 2022;14:1877. [DOI: 10.3390/cancers14081877] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
20 Tőkés AM, Vári-kakas S, Kulka J, Törőcsik B. Tumor Glucose and Fatty Acid Metabolism in the Context of Anthracycline and Taxane-Based (Neo)Adjuvant Chemotherapy in Breast Carcinomas. Front Oncol 2022;12:850401. [DOI: 10.3389/fonc.2022.850401] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
21 Filippi S, Paccosi E, Balzerano A, Ferretti M, Poli G, Taborri J, Brancorsini S, Proietti-de-santis L. CSA Antisense Targeting Enhances Anticancer Drug Sensitivity in Breast Cancer Cells, including the Triple-Negative Subtype. Cancers 2022;14:1687. [DOI: 10.3390/cancers14071687] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Deng S, Leong HC, Datta A, Gopal V, Kumar AP, Yap CT. PI3K/AKT Signaling Tips the Balance of Cytoskeletal Forces for Cancer Progression. Cancers (Basel) 2022;14:1652. [PMID: 35406424 DOI: 10.3390/cancers14071652] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
23 Jiang X, Guo S, Xu M, Ma B, Liu R, Xu Y, Zhang Y. TFAP2C-Mediated lncRNA PCAT1 Inhibits Ferroptosis in Docetaxel-Resistant Prostate Cancer Through c-Myc/miR-25-3p/SLC7A11 Signaling. Front Oncol 2022;12:862015. [DOI: 10.3389/fonc.2022.862015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
24 Fontana F, Anselmi M, Limonta P. Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor Progression. Cancers (Basel) 2022;14:1614. [PMID: 35406386 DOI: 10.3390/cancers14071614] [Reference Citation Analysis]
25 Lee AH, Mejia Peña C, Dawson MR. Comparing the Secretomes of Chemorefractory and Chemoresistant Ovarian Cancer Cell Populations. Cancers (Basel) 2022;14:1418. [PMID: 35326569 DOI: 10.3390/cancers14061418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Farghadani R, Naidu R. Curcumin as an Enhancer of Therapeutic Efficiency of Chemotherapy Drugs in Breast Cancer. Int J Mol Sci 2022;23:2144. [PMID: 35216255 DOI: 10.3390/ijms23042144] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
27 Yu DL, Lou ZP, Ma FY, Najafi M. The interactions of paclitaxel with tumour microenvironment. Int Immunopharmacol 2022;105:108555. [PMID: 35121223 DOI: 10.1016/j.intimp.2022.108555] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
28 Smith ER, Xu XX. Breaking malignant nuclei as a non-mitotic mechanism of taxol/paclitaxel. J Cancer Biol 2021;2:86-93. [PMID: 35048083 DOI: 10.46439/cancerbiology.2.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Jayaraman M, Sivakumar D, Dutta P, Arora K, Raghavendran HRB, Nagarajan K. A Study on the Role of Phytochemicals in the Preclinical Neuronal Cancer Model. Handbook of Animal Models and its Uses in Cancer Research 2022. [DOI: 10.1007/978-981-19-1282-5_31-1] [Reference Citation Analysis]
30 Smith ER, Chen Z, Xu X. Paclitaxel and cancer treatment: Non-mitotic mechanisms of paclitaxel action in cancer therapy. Paclitaxel 2022. [DOI: 10.1016/b978-0-323-90951-8.00005-9] [Reference Citation Analysis]
31 Ruiz de Porras V, Font A, Aytes A. Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives. Cancer Lett 2021;523:162-9. [PMID: 34517086 DOI: 10.1016/j.canlet.2021.08.033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
32 Madamsetty VS, Tavakol S, Moghassemi S, Dadashzadeh A, Schneible JD, Fatemi I, Shirvani A, Zarrabi A, Azedi F, Dehshahri A, Aghaei Afshar A, Aghaabbasi K, Pardakhty A, Mohammadinejad R, Kesharwani P. Chitosan: A versatile bio-platform for breast cancer theranostics. J Control Release 2021;341:733-52. [PMID: 34906606 DOI: 10.1016/j.jconrel.2021.12.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
33 Mohammadinejad R, Madamsetty VS, Kumar A, Varzandeh M, Dehshahri A, Zarrabi A, Sharififar F, Mohammadi M, Fahimipour A, Ramakrishna S. Electrospun nanocarriers for delivering natural products for cancer therapy. Trends in Food Science & Technology 2021;118:887-904. [DOI: 10.1016/j.tifs.2021.10.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 12.0] [Reference Citation Analysis]
34 Mahmoud N, Dawood M, Huang Q, Ng JPL, Ren F, Wong VKW, Efferth T. Nimbolide inhibits 2D and 3D prostate cancer cells migration, affects microtubules and angiogenesis and suppresses B-RAF/p.ERK-mediated in vivo tumor growth. Phytomedicine 2022;94:153826. [PMID: 34775358 DOI: 10.1016/j.phymed.2021.153826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Sasitharan K, Iqbal HA, Bifsa F, Olszewska A, Linton KJ. ABCB1 Does Not Require the Side-Chain Hydrogen-Bond Donors Gln347, Gln725, Gln990 to Confer Cellular Resistance to the Anticancer Drug Taxol. Int J Mol Sci 2021;22:8561. [PMID: 34445264 DOI: 10.3390/ijms22168561] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Español A, Salem A, Sanchez Y, Sales ME. Breast cancer: Muscarinic receptors as new targets for tumor therapy. World J Clin Oncol 2021; 12(6): 404-428 [PMID: 34189066 DOI: 10.5306/wjco.v12.i6.404] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Huang P, Li F, Mo Z, Geng C, Wen F, Zhang C, Guo J, Wu S, Li L, Brünner N, Stenvang J. A Comprehensive RNA Study to Identify circRNA and miRNA Biomarkers for Docetaxel Resistance in Breast Cancer. Front Oncol 2021;11:669270. [PMID: 34055636 DOI: 10.3389/fonc.2021.669270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
38 Doldi V, El Bezawy R, Zaffaroni N. MicroRNAs as Epigenetic Determinants of Treatment Response and Potential Therapeutic Targets in Prostate Cancer. Cancers (Basel) 2021;13:2380. [PMID: 34069147 DOI: 10.3390/cancers13102380] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
39 Manivannan S, Nagaraj S, Narayan S. A Reflection on the Mechanism of the Role of Nanoparticles in Increasing the Efficacy of Anti-tumour Properties of Docetaxel. Curr Pathobiol Rep 2021;9:79-91. [DOI: 10.1007/s40139-021-00223-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
40 Ren Y, Wang Y, Li G, Zhang Z, Ma L, Cheng B, Chen J. Discovery of Novel Benzimidazole and Indazole Analogues as Tubulin Polymerization Inhibitors with Potent Anticancer Activities. J Med Chem 2021;64:4498-515. [PMID: 33788562 DOI: 10.1021/acs.jmedchem.0c01837] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 22.0] [Reference Citation Analysis]
41 Barbolina MV. Dichotomous role of microtubule associated protein tau as a biomarker of response to and a target for increasing efficacy of taxane treatment in cancers of epithelial origin. Pharmacol Res 2021;168:105585. [PMID: 33798735 DOI: 10.1016/j.phrs.2021.105585] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
42 Mirzaei S, Zarrabi A, Asnaf SE, Hashemi F, Zabolian A, Hushmandi K, Raei M, Goharrizi MASB, Makvandi P, Samarghandian S, Najafi M, Ashrafizadeh M, Aref AR, Hamblin MR. The role of microRNA-338-3p in cancer: growth, invasion, chemoresistance, and mediators. Life Sci 2021;268:119005. [PMID: 33421526 DOI: 10.1016/j.lfs.2020.119005] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 33.0] [Reference Citation Analysis]
43 Juanes MA. Cytoskeletal Control and Wnt Signaling-APC's Dual Contributions in Stem Cell Division and Colorectal Cancer. Cancers (Basel) 2020;12:E3811. [PMID: 33348689 DOI: 10.3390/cancers12123811] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]